GPT and type 2 diabetes mellitus: For patients with T2D, decreases in γ-GT, ALP, and total bilirubin were significantly greater than placebo in all pemafibrate groups, and decreases in ALT were significantly greater in groups treated with 0.2 mg/day or above.